Latest Tax Rebates News

Tambourah Metals reports breakthrough high-grade gold discoveries at Beatty Park South and Tambourah King, alongside promising critical minerals assays at Speewah North, underpinning an aggressive exploration push in Western Australia.

BluGlass Limited reports a robust project pipeline exceeding US$100 million, bolstered by initial orders from Collins Aerospace and Infleqtion Inc, alongside strategic board appointments and a $6 million R&D tax rebate.

Noxopharm Limited reports growing interest in its Sofra technology with new research collaborations and a safe, well-tolerated HERACLES trial of SOF-SKN. The company also secures funding extensions to support ongoing development.

Metals Australia Limited has reported a 3.3-fold increase in its Lac Carheil Graphite project resource, now totaling 50 million tonnes at 10.2% graphite content, while progressing key studies for a battery anode material plant in Quebec.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Latrobe Magnesium successfully commissioned its Demonstration Plant producing magnesium oxide and secured $10 million in funding, while receiving a $200 million financing interest from the U.S. Export Import Bank for its next-stage commercial plant.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Weebit Nano has reported a record quarter with A$7.3 million in customer receipts, securing three key product agreements and progressing critical technology milestones at leading semiconductor fabs.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

South Harz Potash Limited is progressing its transition to a dual-asset strategy, raising A$2.58 million to support expansion while adopting a cautious approach to its core German potash project amid market weakness.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

Memphasys Limited has disclosed a $1.118 million liability linked to its FY24 R&D tax rebate following an ASX inquiry, while confirming compliance with continuous disclosure rules and ongoing engagement with the ATO for a private ruling.